



Dicerna to Present at Jefferies 2017 Global Healthcare Conference

CAMBRIDGE, Mass., June 1, 2017 -- Dicerna Pharmaceuticals, Inc. (Nasdaq: DRNA), a leading developer of investigational ribonucleic acid interference (RNAi) therapeutics, today announced that Douglas M. Fambrough, Ph.D., president and chief executive officer, will present at the Jefferies 2017 Global Healthcare Conference on Friday, June 9, 2017, at 11:30 a.m. ET. The conference will be held at the Grand Hyatt New York in New York City.

A live webcast of the presentation can be accessed on the Investors & Media section on the Dicerna website at www.dicerna.com. An archived replay of the webcast will be available on the Company's website after the conference.

About Dicerna Pharmaceuticals, Inc.

Dicerna Pharmaceuticals, Inc. is a biopharmaceutical company focused on the discovery and development of innovative ribonucleic acid interference (RNAi)-based therapeutics for diseases involving the liver, including rare diseases, chronic liver diseases, cardiovascular diseases, and viral infectious diseases. The Company is leveraging its proprietary GalXC™ RNAi technology platform to build a broad pipeline in these core therapeutic areas, focusing on target genes where connections between target gene and diseases are well understood and documented. The Company intends to discover, develop and commercialize novel therapeutics either on its own or in collaboration with pharmaceutical partners. For more information, please visit www.dicerna.com.

Investor Contact:

Rx Communications Group
Paula Schwartz, 917-322-2216
pschwartz@rxir.com

Media Contact:

SmithSolve
Alex Van Rees, 973-442-1555 ext. 111
alex.vanrees@smithsolve.com